SCEMBLIX is a brand name for the drug asciminib, which is a targeted therapy used in the treatment of chronic myeloid leukemia (CML), a type of cancer that affects the white blood cells. It is specifically designed for patients who have been previously treated with two or more tyrosine kinase inhibitors (TKIs) and for those who have the T315I mutation, a genetic alteration that makes CML resistant to other treatments. SCEMBLIX works by selectively inhibiting the activity of the ABL1 kinase, a protein that plays a crucial role in the growth and development of leukemia cells, thereby slowing down or stopping the progression of the disease. This medication is taken orally and is known for its potential to provide a therapeutic option with a different mechanism of action compared to traditional TKIs, offering hope for patients with limited treatment options.